GlassScriptPhysician profile
Isabella Agrela DO Nascimento
NPI 1598492340
$1,380.30
in general payments reported to CMS, 2019-2025
16 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.35 · 2023: $346 · 2024: $553 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $377.90 | 2024-2025 | Rybrevant, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $129.42 | 2024 | Opdivo |
| Stemline Therapeutics INC. | $117.80 | 2023 | Orserdu |
| Merck Sharp & Dohme LLC | $117.31 | 2023 | Keytruda |
| Novocure INC. | $110.76 | 2023 | |
| Daiichi Sankyo INC. | $87.08 | 2024-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $72.43 | 2022-2025 | Ninlaro, Iclusig |
| Genentech USA, INC. | $68.01 | 2024-2025 | Phesgo, Tecentriq, Itovebi |
| Astrazeneca Pharmaceuticals LP | $62.32 | 2025 | |
| Incyte Corporation | $61.85 | 2024-2025 | Jakafi |
| Celgene Corporation | $52.32 | 2024-2025 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $45.70 | 2025 | Vyloy |
| Genzyme Corporation | $24.10 | 2024 | |
| Geron Corporation | $19.48 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $18.54 | 2025 | Ultomiris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.28 | 2025 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabella Agrela DO Nascimento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.